- Home
- CCAQ vs CUE Comparison
CCAQ vs CUE Comparison
Compare CCAQ & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
BUY
Current Price
$17.25
Company Overview
Basic Information| Metric | CCAQ | CUE |
|---|---|---|
| Founded | 2024 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.4M | 177.0M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CCAQ | CUE |
|---|---|---|
| Price | $10.55 | $17.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $88.00 |
| AVG Volume (30 Days) | 2.9K | ★ 372.4K |
| Earning Date | 08-12-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.11 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $27,466,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 195.75 |
| 52 Week Low | $10.43 | $0.17 |
| 52 Week High | $10.88 | $45.50 |
Technical Indicators
Market Signals| Indicator | CCAQ | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 59.82 | 34.10 |
| Support Level | $10.46 | $0.24 |
| Resistance Level | $10.70 | $33.95 |
| Average True Range (ATR) | 0.07 | 2.72 |
| MACD | -0.01 | -0.91 |
| Stochastic Oscillator | 54.32 | 4.10 |
Price Performance
Historical Comparison CCAQ
CUE
About CCAQ Collective Acquisition Corp. Class A Ordinary Shares
Collective Acquisition Corp is a blank check company.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage therapeutics company focused on advancing a robust portfolio of potentially transformative therapies aimed at enabling functional cures across immunological disorders. Its product pipeline includes CUE-221, an anti-IgE antibody candidate being developed for allergic diseases. The company has also developed the Immuno-STAT platform for targeting disease-related T cells and is developing CUE-401, an IL-2 and TGF-B therapeutic candidate for autoimmune diseases.